Overview

A Study to Evaluate the Safety and Efficacy of an Investigational Drug in HIV Infected Patients (0518-004)(COMPLETED)

Status:
Completed
Trial end date:
2010-07-01
Target enrollment:
0
Participant gender:
All
Summary
This is a study that will investigate the safety and efficacy of an investigational drug in Human immunodeficiency virus (HIV) infected patients.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Efavirenz
Lamivudine
Raltegravir Potassium
Tenofovir
Criteria
Inclusion Criteria:

- Patient must be HIV positive who must have received less than 7 days total of any
antiretroviral therapy (HIV related therapy)

Extension Studies:

- First extension: Patient completed the 48-week base study

- Second extension: Patient completed the first 144-week extension study

Exclusion Criteria:

- Less than 18 years of age

- Individuals who currently do not test positive for HIV